Fundamental Analysis of KARYOPHARM THERAPEUTICS INC(NASDAQ:KPTI) stock

Fundamental Rating

Taking everything into account, KPTI scores 2 out of 10 in our fundamental rating. KPTI was compared to 588 industry peers in the Biotechnology industry. Both the profitability and financial health of KPTI have multiple concerns. KPTI is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year KPTI has reported negative net income.

KPTI had a negative operating cash flow in the past year.

KPTI had negative earnings in each of the past 5 years.

In the past 5 years KPTI always reported negative operating cash flow.

1.2 Ratios

KPTI has a Return On Assets (-59.49%) which is in line with its industry peers.

		Industry Rank	Sector Rank
ROA	-59.49%
ROE	N/A
ROIC	N/A

ROA(3y)-48.77%

ROA(5y)-55.33%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 96.59%, KPTI belongs to the top of the industry, outperforming 97.09% of the companies in the same industry.

KPTI's Gross Margin has been stable in the last couple of years.

The Profit Margin and Operating Margin are not available for KPTI so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	96.59%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-0.3%

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

KPTI does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, KPTI has more shares outstanding

KPTI has more shares outstanding than it did 5 years ago.

KPTI has a worse debt/assets ratio than last year.

2.2 Solvency

KPTI has an Altman-Z score of -8.77. This is a bad value and indicates that KPTI is not financially healthy and even has some risk of bankruptcy.

The Altman-Z score of KPTI (-8.77) is worse than 74.70% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-8.77

ROIC/WACCN/A

WACC3.79%

2.3 Liquidity

A Current Ratio of 3.37 indicates that KPTI has no problem at all paying its short term obligations.

KPTI's Current ratio of 3.37 is on the low side compared to the rest of the industry. KPTI is outperformed by 61.71% of its industry peers.

A Quick Ratio of 3.32 indicates that KPTI has no problem at all paying its short term obligations.

KPTI has a worse Quick ratio (3.32) than 60.85% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	3.37
Quick Ratio	3.32

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 38.42% over the past year.

The Revenue has decreased by -7.04% in the past year.

The Revenue has been growing by 36.96% on average over the past years. This is a very strong growth!

EPS 1Y (TTM)38.42%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q16.28%

Revenue 1Y (TTM)-7.04%

Revenue growth 3Y10.55%

Revenue growth 5Y36.96%

Revenue growth Q2Q0.44%

3.2 Future

The Earnings Per Share is expected to grow by 17.84% on average over the next years. This is quite good.

Based on estimates for the next years, KPTI will show a very strong growth in Revenue. The Revenue will grow by 24.31% on average per year.

EPS Next Y-0.37%

EPS Next 2Y8.33%

EPS Next 3Y15.18%

EPS Next 5Y17.84%

Revenue Next Year-0.8%

Revenue Next 2Y5.61%

Revenue Next 3Y16.12%

Revenue Next 5Y24.31%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for KPTI. In the last year negative earnings were reported.

Also next year KPTI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as KPTI's earnings are expected to grow with 15.18% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y8.33%

EPS Next 3Y15.18%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for KPTI!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

KARYOPHARM THERAPEUTICS INC

NASDAQ:KPTI (4/19/2024, 7:00:22 PM)

After market: 1.15 -0.02 (-1.71%)

1.17

-0.11 (-8.59%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap134.63M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-59.49%
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	96.59%
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.61

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	3.37
Quick Ratio	3.32
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)38.42%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y-0.37%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-7.04%

Revenue growth 3Y10.55%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

KARYOPHARM THERAPEUTICS INC (KPTI)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens